AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 530249: Pentadecane, 7-butyl-8-propyl

Chemical compound data from PubChem database. IUPAC Name: 7-butyl-8-propylpentadecane. Molecular Formula: C22H46. Molecular Weight: 310.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Program Instruction (PI-08-03)

This Program Instruction (PI) provides instruction to states on the June 30, 2008 submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Social Security Act (the Act), the Child Abuse Prevention and Treatment Act (CAPTA), and the Chafee Foster Care Independence Program (CFCIP), including the ETV program; the submission of the CFS-101, Part I, Annual Budget Request, Part II, Annual Summary of Child and Family Services, and Part III, Annual Expenditure Report—Title IV-B, Subparts 1 and 2, CFCIP and ETV.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401694-T1: [Translated] HIGH DUTY RATIO OFFSET VOLTAGE COMPENSATION FOR OPERATIONAL AMPLIFIER

A circuit arrangement comprising an input amplifier stage (31) with two inputs (36, 37) and an output (34) being connectable to an input (35) of an output amplifier stage (32). The circuit furthermore comprises a comparator (33) with a first input (41), a second input (42) and a comparator output (44), a feedback capacitor (43) connected to an offset tuning input (45) of the input amplifier stage (31), and a plurality of switches (S1, S2) that are controllable by switching signals (V1, V2) to allow the circuit to be switched from a first phase to a second phase. During the first phase (1), the output (34) and the input (35) are separated by a first one of the switches (S2) and the two inputs (36, 37) are connected via a second one of the switches (S1). The first input (41) of the comparator (33) is connected to the output (34) of the input amplifier stage (31) and the second input (42) of the comparator (33) is connected to the input (35) of the output amplifier stage (32) such that via the comparator output (44) a charge on the feedback capacitor (43), and hence the voltage at the offset tuning input (45) is altered and an offset of the input amplifier stage (31) is corrected.
Compound 527794: But-2-enyl 3-chlorobenzoate

Chemical compound data from PubChem database. IUPAC Name: but-2-enyl 3-chlorobenzoate. Molecular Formula: C11H11ClO2. Molecular Weight: 210.65. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The evolutionary position of nematodes

Background
          The complete genomes of three animals have been sequenced by global research efforts: a nematode worm (Caenorhabditis elegans), an insect (Drosophila melanogaster), and a vertebrate (Homo sapiens). Remarkably, their relationships have yet to be clarified. The confusion concerns the enigmatic position of nematodes. Traditionally, nematodes have occupied a basal position, in part because they lack a true body cavity. However, the leading hypothesis now joins nematodes with arthropods in a molting clade, Ecdysozoa, based on data from several genes.
        
        
          Results
          We tested the Ecdysozoa hypothesis with analyses of more than 100 nuclear protein alignments, under conditions that would expose biases, and found that it was not supported. Instead, we found significant support for the traditional hypothesis, Coelomata. Our result is robust to different rates of sequence change among genes and lineages, different numbers of taxa, and different species of nematodes.
        
        
          Conclusion
          We conclude that insects (arthropods) are genetically and evolutionarily closer to humans than to nematode worms.
Airway pressure release ventilation increases cardiac performance in patients with acute lung injury/adult respiratory distress syndrome

Background
          The purpose of the present study is to determine whether airway pressure release ventilation (APRV) can safely enhance hemodynamics in patients with acute lung injury (ALI) and/or adult respiratory distress syndrome (ARDS), relative to pressure control ventilation (PCV).
        
        
          Method
          Patients with severe acute lung injury or ARDS who were managed with inverse-ratio pressure control ventilation, neuromuscular blockade and a pulmonary artery catheter were switched to APRV. Hemodynamic performance, as well as pressor and sedative needs, was assessed after discontinuing neuromuscular blockade
        
        
          Results
          Mean age was 58 ± 9 years (n = 12) and mean Lung Injury Score was 7.6 ± 2.1. Temperature and arterial oxygen tension/fractional inspired oxygen (FiO2) were similar among the patients. Peak airway pressures fell from 38 ± 3 for PCV to 25 ± 3 cmH2O for APRV, and mean pressures fell from 18 ± 3 for PCV to 12 ± 2 cmH2O for APRV. Paralytic use and sedative use were significantly lower with APRV than with PCV. Pressor use decreased substantially with ARPV. Lactate levels remained normal, but decreased on APRV. Cardiac index rose from 3.2 ± 0.4 for PCV to 4.6 ± 0.3 l/min per m2 body surface area (BSA) for APRV, whereas oxygen delivery increased from 997 ± 108 for PCV to 1409 ± 146 ml/min for APRV, and central venous pressure declined from 18 ± 4 for PCV to 12 ± 4 cmH2O for APRV. Urine output increased from 0.83 ± 0.1 for PCV to 0.96 ± 0.12 ml/kg per hour for APRV.
        
        
          Conclusion
          APRV may be used safely in patients with ALI/ARDS, and decreases the need for paralysis and sedation as compared with PCV-inverse ratio ventilation (IRV). APRV increases cardiac performance, with decreased pressor use and decreased airway pressure, in patients with ALI/ARDS.
Compound 529857: Myricetin, TMS

Chemical compound data from PubChem database. IUPAC Name: 3,5,7-tris(trimethylsilyloxy)-2-[3,4,5-tris(trimethylsilyloxy)phenyl]chromen-4-one. Molecular Formula: C33H58O8Si6. Molecular Weight: 751.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients

Background
          Though the dysfunction of central dopaminergic system has been proposed, the etiology or pathogenesis of schizophrenia is still uncertain partly due to limited accessibility to dopamine receptor. The purpose of this study was to define whether or not the easily accessible dopamine receptors of peripheral lymphocytes can be the peripheral markers of schizophrenia.
        
        
          Results
          44 drug-medicated schizophrenics for more than 3 years, 28 drug-free schizophrenics for more than 3 months, 15 drug-naïve schizophrenic patients, and 31 healthy persons were enrolled. Sequential reverse transcription and quantitative polymerase chain reaction of the mRNA were used to investigate the expression of D3 and D5 dopamine receptors in peripheral lymphocytes. The gene expression of dopamine receptors was compared in each group. After taking antipsychotics in drug-free and drug-naïve patients, the dopamine receptors of peripheral lymphocytes were sequentially studied 2nd week and 8th week after medication.
          In drug-free schizophrenics, D3 dopamine receptor mRNA expression of peripheral lymphocytes significantly increased compared to that of controls and drug-medicated schizophrenics, and D5 dopamine receptor mRNA expression increased compared to that of drug-medicated schizophrenics. After taking antipsychotics, mRNA of dopamine receptors peaked at 2nd week, after which it decreases but the level was above baseline one at 8th week. Drug-free and drug-naïve patients were divided into two groups according to dopamine receptor expression before medications, and the group of patients with increased dopamine receptor expression had more severe psychiatric symptoms.
        
        
          Conclusions
          These results reveal that the molecular biologically-determined dopamine receptors of peripheral lymphocytes are reactive, and that increased expression of dopamine receptor in peripheral lymphocyte has possible clinical significance for subgrouping of schizophrenis.
2014 CMHS Uniform Reporting System (URS) Table for Maryland

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Maryland. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Adenovirus type 7 associated with severe and fatal acute lower respiratory infections in Argentine children

Background
          Adenoviruses are the second most prevalent cause of acute lower respiratory infection of viral origin in children under four years of age in Buenos Aires, Argentina. The purpose of this study was to analyze the clinical features and outcome of acute lower respiratory infection associated with different adenovirus genotypes in children.
        
        
          Methods
          Twenty-four cases of acute lower respiratory infection and adenovirus diagnosis reported in a pediatric unit during a two-year period were retrospectively reviewed. Adenovirus was detected by antigen detection and isolation in HEp-2 cells. Adenovirus DNA from 17 isolates was studied by restriction enzyme analysis with Bam HI and Sma I.
        
        
          Results
          Subgenus b was found in 82.3% of the cases, and subgenus c in 17.7%. Within subgenus b, only genotype 7 was detected, with genomic variant 7h in 85.7% (12/14) and genomic variant 7i in 14.3% (2/14).
          Mean age was 8.8 ±; 6 months, and male to female ratio was 3.8: 1. At admission, pneumonia was observed in 71% of the cases and bronchiolitis in 29%. Malnutrition occurred in 37% of the cases; tachypnea in 79%; chest indrawing in 66%; wheezing in 58%; apneas in 16%; and conjunctivitis in 29%. Blood cultures for bacteria and antigen detection of other respiratory viruses were negative.
          During hospitalization, fatality rate was 16.7% (4 /24). Of the patients who died, three had Ad 7h and one Ad 7i. Thus, fatality rate for adenovirus type 7 reached 28.6% (4/14).
        
        
          Conclusions
          These results show the predominance of adenovirus 7 and high lethality associated with the genomic variants 7h and 7i in children hospitalized with acute lower respiratory infection.
Compound 526655: N-Acetylmethamphetamine

Chemical compound data from PubChem database. IUPAC Name: N-methyl-N-(1-phenylpropan-2-yl)acetamide. Molecular Formula: C12H17NO. Molecular Weight: 191.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg

In recent years, the effectiveness of anti-TNF therapy in treating rheumatoid arthritis (RA) has become apparent. While trials of IL-1 receptor antagonist in RA have been encouraging, it clearly is more difficult to target two molecules (IL-1 α and β) than one (TNF-α). In his review article, Professor Wim van den Berg argues that both TNF-α and IL-1 must be blocked in RA and that although TNF is clearly a potent inflammatory molecule, the dominant cytokine in the subsequent degradation of the joint tissue is IL-1. This commentary discusses his hypothesis in light of animal studies and the limitations of the conclusions that can be drawn from them. More broadly, it discusses the biology of TNF-α and IL-1 and suggests explanations of why TNF-α is a pivotal cytokine in this disease.
National Tribal TANF Characteristics Data (FY2008 - FY2015)

The Office of Family Assistance, Division of Tribal TANF has posted National Tribal TANF characteristics data for fiscal years (FY) 2008, 2009, 2010, 2011, 2012, 2013, 2014, and 2015 The characteristics data has been produced in tables for the following categories of information: Number of individuals participating in Tribal TANF work activities, by activity; Adults by work participation status; Adults by relationship to head of household; Types of families receiving assistance (e.g., one-parent, two-parent, child-only); Families by the number of children in the family; Average age of recipient children.

<b>Units of Response: </b>Tribal TANF Programs

<b>Type of Data: </b>Administrative

<b>Tribal Data: </b>Yes

<b>COVID-19 Data: </b>No

<b>Periodicity: </b>Annual

<b>SORN: </b>https://www.federalregister.gov/documents/2015/04/02/2015-07440/privacy-act-of-1974-system-of-records-notice

<b>Data Use Agreement: </b>Unavailable

<b>Data Use Agreement Location: </b>Unavailable

<b>Equity Indicators: </b>Disability;Household Size;Indigenous Population

<b>Granularity: </b>Tribe

<b>Spatial: </b>United States

<b>Geocoding: </b>Region;Tribe
Compound 528824: 3,7,11-Trimethyldodec-1-en-3-ol

Chemical compound data from PubChem database. IUPAC Name: 3,7,11-trimethyldodec-1-en-3-ol. Molecular Formula: C15H30O. Molecular Weight: 226.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528640: Trimethylsilyl 2-([(trimethylsilyl)oxy]methyl)butanoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(trimethylsilyloxymethyl)butanoate. Molecular Formula: C11H26O3Si2. Molecular Weight: 262.49. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525646: N,N-Dimethyl-N'-phenyl-p-chlorobenzamidine

Chemical compound data from PubChem database. IUPAC Name: 4-chloro-N,N-dimethyl-N'-phenylbenzenecarboximidamide. Molecular Formula: C15H15ClN2. Molecular Weight: 258.74. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child and Family Services Reviews Update Volume 14, Issue 2, April 2020

This issue of Child and Family Services Reviews Update contains the following sections: CB Response to COVID-19 Pandemic, CFSR Technical Bulletin #11, Enhancements to the Data Indicator Visualizations, State Data Profiles Released, ACYF-CB-PI-20-02— State Guidance on FY 2021 APSR, Status of Approved PIPs, and PIP Evaluation During Non-Overlapping Data Periods.

Metadata-only record linking to the original dataset. Open original dataset below.
Number of Malignant Neoplasm Deaths among Maryland Residents, 1920-2015

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated 8/14/2024. 

Number of deaths among Maryland residents for which malignant neoplasms were the underlying cause of death.  This includes deaths coded to the following International Classification of Diseases codes:
ICD-3 (1920-1929) -- 43-49
ICD-4 (1930-1938) -- 45-53, 72
ICD-5 (1939-1948) -- 45-55
ICD-6 (1949-1957) -- 140-205
ICD-7 (1958-1967) -- 140-205
ICD-8 (1968-1978) -- 140-209
ICD-9 (1979-1998) -- 140-208
ICD-10 (1999-present) -- C00-C97.
CDC WONDER: Population (from Census)

<p>The Population online databases contain data from the US Census Bureau. The Census Estimates online database contains county-level population counts for years 1970 - 2000. The data comprise the April 1st Census counts for years 1970, 1980, 1990 and 2000, the July 1st intercensal estimates for years 1971-1979 and 1981-1989, and the July 1st postcensal estimates for years 1991-1999. The Census Projections online database contains population projections for years 2004-2030 by year, state, age, race and sex, produced by the Census Bureau in 2005. The data are produced by the United States Department of Commerce, U.S. Census Bureau, Population Division.</p>
Patent AT-E401288-T1: [Translated] REDISPERSIBLE DISPERSION POWDER FOR THERMAL INSULATION COMPOSITE SYSTEMS

The present invention relates to the use of water-redispersible dispersion powders based on one or more copolymers which are stabilized with at least one protective colloid in the production of composite thermal insulation systems, wherein the copolymer or copolymers contain(s) monomers containing carbonyl groups.
Lactate: A key metabolite in the intercellular metabolic interplay

Most physicians involved in intensive care consider lactate solely as a deleterious metabolite, responsible for high morbidity and bad prognosis in severe patients. For the physiologist, however, lactate is a key metabolite, alternatively produced or consumed. Many studies in the literature have infused animals or humans with exogenous lactate, demonstrating its safety and usefulness, but the bad reputation of lactate is still widespread. The metabolic meaning of glucose–lactate cycling exceeds its initial role described by Cori and Cori. According to recent works concerning lactate, it can be predicted that a new role as a therapeutic agent will arise for this metabolite.
National Admissions to Substance Abuse Treatment Services - The Treatment Episode Data Set (TEDS) 1992-2001

This report presents results from the Treatment Episode Data Set (TEDS) for 2001 and trend data for 1992-2001. The report provides information on the demographic and substance abuse characteristics of the 1.7 million people admitted to treatment for abuse of alcohol and drugs in 2001 to facilities that report to individual state administrative data systems.
Low frequency of mutations in the core promoter and precore regions of hepatitis B virus in anti-HBe positive Brazilian carriers

Background
          Mutations in the core promoter and precore regions of the hepatitis B virus (HBV) genome, notably the double substitution (AGG to TGA) at nt positions 1762-1764 in the core promoter, and the precore stop codon mutation G to A at nt 1896, can often explain the anti-HBe phenotype in chronic carriers. However, the A1896 mutation is restricted to HBV isolates that have T at nt 1858. The double substitution at positions 1762-1764 has been described to occur preferentially in patients infected with strains showing C instead of T at nt 1858.
        
        
          Results
          HBV DNAs from 29 anti-HBe Brazilian samples were characterized by nucleotide sequencing of PCR products from precore region. Among them, 18 isolates presented C at nt 1858 (mostly genotype A strains). The 11 remaining isolates (genotypes D and F) had T1858. The stop codon mutation at nt 1896 was found in seven isolates (24% of the total and 63% of the isolates that had T1858). The frequency of the double substitution at positions 1762-1764 was surprisingly low (20%) among C1858 isolates. An association between A1896 and TGA 1762-1764 mutations was observed among genotype D isolates: these showed either none of the two mutations or both. Furthermore, strains mutated at positions 1896 and/or 1762-1764 also presented an elevated number of other, less common substitutions in the core promoter and precore regions.
        
        
          Conclusions
          The data reported here are not in accordance with some reports from other parts of the world. In half of the isolates, none of the mutations previously described could explain the anti-HBe phenotype.
Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion

Background
          Angiotensin converting enzyme inhibitors are routinely prescribed to patients with chronic kidney disease because of their known renoprotective effects. We evaluated the effect of short-term therapy with the angiotensin converting enzyme inhibitor, enalapril, in early Alport syndrome, defined as disease duration less than 10 years and a normal glomerular filtration rate.
        
        
          Methods
          11 children with early Alport syndrome were investigated. Two consecutive early morning urine specimens were collected at the start of the study for measurement of urinary creatinine, total protein, albumin, TGF-β, and nitrite excretion. Patients were treated with enalapril, ≅ 0.2 mg/kg/day, once a day for 14 days. Two early morning urine specimens were collected on days 13 and 14 of enalapril treatment and two weeks later for measurement of urinary creatinine, total protein, albumin, TGF-β, and nitrite excretion.
        
        
          Results
          Prior to treatment, urinary excretion of transforming growth factor-β and nitrite, the major metabolite of nitric oxide, was within normal limits in all patients. Administration of enalapril for 2 weeks did not alter urinary albumin, transforming growth factor-β, or nitrite excretion.
        
        
          Conclusion
          These findings suggest that early Alport syndrome represents a disease involving exclusively intrinsic glomerular barrier dysfunction. At this stage of the illness, there is no evidence of angiotensin II-mediated proteinuria or increased production of transforming growth factor-β and, therefore, routine treatment with an angiotensin converting enzyme inhibitor may not be warranted.
Initial Design and Implementation Report and Subsequent Quarterly Progress Reports Templates

This template outlines what should be included in the Initial Design and Implementation Report and includes guidance for each heading. This report is typically due 90 days after the agency signs and accepts the waiver terms and conditions and serves as the first Quarterly Progress Report. This template outlines what should be included in the Quarterly Progress Report, which is due every 90 days after the agency signs and accepts the waiver terms and conditions during the developmental phase (i.e., before implementation begins), and what should be included in the Semiannual Progress Report, which is due every 180 days after implementation begins.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399662-T1: [Translated] METHOD FOR FIXING FIXING RINGS ON STABILIZERS FOR MOTOR VEHICLES

In a process for nonpositively joining metallic fixing rings made of a single piece to a stabiliser for motor vehicles, the fixing rings are slipped over the ends of the stabiliser, placed in their fastening position then nonpositively joined to the stabiliser by plastic deformation of the fixing ring. In order to develop such a process in such a way that damage to the surface of the stabiliser is avoided, at least one section of the inner surface of the fixing ring does not lie on the stabiliser in the fastening position, and the deformation forces that cause the plastic deformation of the fixing ring are applied in the region of this non-contacting section of the fixing ring.